塞德斯医疗 CLDX 深 沪
等待开盘 10-15 09:30:00 美东时间
27.835
-0.415
-1.47%
华盛通- 最 高28.73
- 今 开28.49
- 成交量 104.43万股
- 最 低 27.68
- 昨 收 28.25
- 总市值 21.86亿
- 52周最高 45.14
- 市盈率 静 --
- 换手率 1.33%
- 52周最低 22.10
- 委 比 84.90%
- 总股本 7852.95万
- 历史最高 582.60
- 量 比 0.57
- 振 幅 3.72%
- 历史最低 1.50
- 每 手 1
- 风险率 5.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多塞德斯医疗(CLDX)CSU治疗药物两项III期试验达终点，拟2027年提交BLA
经济观察网 塞德斯医疗（CLDX）研发的barzolvolimab治疗慢性自发性荨麻疹的两项III期试验达终点，计划2027年向FDA提交BLA。 产品研发进展...
10-08 21:05
美股大行评级 | 潜在涨幅405.62%！Inventiva(IVA)获Truist Securities上调目标价至18美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持Inventiva"买入"评级，目标价从13美元升至18美元；富瑞：维持Sagimet Biosciences"买入"评级，目标价从25美元升至26美元
10-05 16:26
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $64 price target.
10-02 20:37
美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
美股大行评级 | Muse热度发酵，Meta目标价获大幅升至875美元；闪迪获看好至2400美元，潜在升幅约27%
今日重点评级关注：Citizens：上调Quince Therapeutics评级至"跑赢大市"，目标价77美元；康托·菲茨杰拉德：维持塞德斯医疗"超配"评级，目标价从61美元升至72美元
09-23 15:30
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday shared topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials. The studies evaluate barzolvolimab for patients with chronic spontaneous urticaria (CSU) who experience inadequate symptom control using H1-antihistamines, includin...
09-23 00:25
Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72
Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $61 to $72.
09-22 23:33
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
Celldex reported positive Phase 3 results for barzolvolimab in chronic spontaneous urticaria (CSU), showing rapid, profound, and sustained efficacy across both dose groups. The studies met primary and key secondary endpoints at Week 12, with significant improvements in UAS7 scores and complete response rates. Barzolvolimab demonstrated strong differentiation in omalizumab-refractory and severe CSU populations, with a favorable safety profile. Eff...
09-22 10:58
美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $46 to $50.
09-11 01:28
